TG Therapeutics, Inc. (TGTX): Depreciation & Amortization
$59.0K
Year ended 2025-12-31
$123.0K
Trailing 12 months to 2026-06-30
-42.0%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.0K | -13.2% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $68.0K | -67.8% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $211.0K | -30.4% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $303.0K | +7.4% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $282.0K | n/a | 2024-02-29, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $59.0K | -13.2% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $91.63M | -6.7% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $35.00M | -2.8% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $15.27M | +12.1% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.55M | -8.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $13.31M | +7.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $91.56M | +13.9% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $91.02M | +15.5% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $24.24M | +2.6% |
Compare TGTX, OPK, RARE, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗